[
  {
    "ts": null,
    "headline": "Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q1 2025 Update",
    "summary": "Read here for an update on key Q1 2025 portfolio moves by Duquesne Family Office. Get insights into top holdings, new investments, exits, and strategy trends.",
    "url": "https://finnhub.io/api/news?id=4fbed0ca23627e54f3c9c093e3f9ca51982b49c9d52c0ce72f846794947bd184",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748296459,
      "headline": "Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q1 2025 Update",
      "id": 134704705,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1473159542/image_1473159542.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Read here for an update on key Q1 2025 portfolio moves by Duquesne Family Office. Get insights into top holdings, new investments, exits, and strategy trends.",
      "url": "https://finnhub.io/api/news?id=4fbed0ca23627e54f3c9c093e3f9ca51982b49c9d52c0ce72f846794947bd184"
    }
  },
  {
    "ts": null,
    "headline": "Should Everyone Be Taking Ozempic? Doctors Say More People Could Benefit",
    "summary": "GLP-1 drugs for weight loss and treating diabetes show promise for an ever-expanding list of diseases.",
    "url": "https://finnhub.io/api/news?id=900fb9a32afabb80268cc243cc31cfaf120a07e546444d03ec0dd89aa4ecd7ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748224800,
      "headline": "Should Everyone Be Taking Ozempic? Doctors Say More People Could Benefit",
      "id": 134715843,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "GLP-1 drugs for weight loss and treating diabetes show promise for an ever-expanding list of diseases.",
      "url": "https://finnhub.io/api/news?id=900fb9a32afabb80268cc243cc31cfaf120a07e546444d03ec0dd89aa4ecd7ce"
    }
  },
  {
    "ts": null,
    "headline": "The Next Big Theme: May 2025",
    "summary": "Big Tech players will collectively spend over $300 billion on AI-focused infrastructure this year to support the growing demands of AI development.",
    "url": "https://finnhub.io/api/news?id=2ec1722c1fd3dd0ca6179f64d76aa2cbe85ffb1b49915bef806400f6abff7bff",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748223900,
      "headline": "The Next Big Theme: May 2025",
      "id": 134697679,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2140491017/image_2140491017.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Big Tech players will collectively spend over $300 billion on AI-focused infrastructure this year to support the growing demands of AI development.",
      "url": "https://finnhub.io/api/news?id=2ec1722c1fd3dd0ca6179f64d76aa2cbe85ffb1b49915bef806400f6abff7bff"
    }
  },
  {
    "ts": null,
    "headline": "Is Novo Nordisk Immune To President Trump's Drug Price Plans",
    "summary": "Discover why Novo Nordisk's stock surged despite CEO changes, driven by GLP-1 success, record sales, and a $2.2B deal to combat obesity.",
    "url": "https://finnhub.io/api/news?id=58764c7eb5c1f7c305fb5b3175bab417232eab2adfadc7b42fac43f6eea5bcce",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748218034,
      "headline": "Is Novo Nordisk Immune To President Trump's Drug Price Plans",
      "id": 134697300,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1453973904/image_1453973904.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover why Novo Nordisk's stock surged despite CEO changes, driven by GLP-1 success, record sales, and a $2.2B deal to combat obesity.",
      "url": "https://finnhub.io/api/news?id=58764c7eb5c1f7c305fb5b3175bab417232eab2adfadc7b42fac43f6eea5bcce"
    }
  }
]